Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Thangirala Sudha, Murat Yalcin, Hung Yun Lin, Ahmed M. Elmetwally, Tipu Nazeer, Thiruvengadam Arumugam, Patricia Phillips, Shaker A. Mousa

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.
原文英語
頁(從 - 到)25-33
頁數9
期刊Cancer Letters
350
發行號1-2
DOIs
出版狀態已發佈 - 八月 1 2014

指紋

Low Molecular Weight Heparin
Pancreatic Neoplasms
Heparin
gemcitabine
Neoplasms
Angiogenesis Inhibitors
Tumor Burden
Hemostasis
Necrosis
Hemorrhage
Neoplasm Metastasis
Growth
tinzaparin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

引用此文

Sudha, T., Yalcin, M., Lin, H. Y., Elmetwally, A. M., Nazeer, T., Arumugam, T., ... Mousa, S. A. (2014). Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Letters, 350(1-2), 25-33. https://doi.org/10.1016/j.canlet.2014.04.016

Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. / Sudha, Thangirala; Yalcin, Murat; Lin, Hung Yun; Elmetwally, Ahmed M.; Nazeer, Tipu; Arumugam, Thiruvengadam; Phillips, Patricia; Mousa, Shaker A.

於: Cancer Letters, 卷 350, 編號 1-2, 01.08.2014, p. 25-33.

研究成果: 雜誌貢獻文章

Sudha, T, Yalcin, M, Lin, HY, Elmetwally, AM, Nazeer, T, Arumugam, T, Phillips, P & Mousa, SA 2014, 'Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin', Cancer Letters, 卷 350, 編號 1-2, 頁 25-33. https://doi.org/10.1016/j.canlet.2014.04.016
Sudha, Thangirala ; Yalcin, Murat ; Lin, Hung Yun ; Elmetwally, Ahmed M. ; Nazeer, Tipu ; Arumugam, Thiruvengadam ; Phillips, Patricia ; Mousa, Shaker A. / Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. 於: Cancer Letters. 2014 ; 卷 350, 編號 1-2. 頁 25-33.
@article{aaa08a5899344cf28f9a90d5a131952d,
title = "Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin",
abstract = "Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.",
keywords = "Anti-cancer, Low molecular weight heparin, Non-anticoagulant heparin, Pancreatic cancer, Tumor suppressor, Tumor survival",
author = "Thangirala Sudha and Murat Yalcin and Lin, {Hung Yun} and Elmetwally, {Ahmed M.} and Tipu Nazeer and Thiruvengadam Arumugam and Patricia Phillips and Mousa, {Shaker A.}",
year = "2014",
month = "8",
day = "1",
doi = "10.1016/j.canlet.2014.04.016",
language = "English",
volume = "350",
pages = "25--33",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

AU - Sudha, Thangirala

AU - Yalcin, Murat

AU - Lin, Hung Yun

AU - Elmetwally, Ahmed M.

AU - Nazeer, Tipu

AU - Arumugam, Thiruvengadam

AU - Phillips, Patricia

AU - Mousa, Shaker A.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

AB - Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

KW - Anti-cancer

KW - Low molecular weight heparin

KW - Non-anticoagulant heparin

KW - Pancreatic cancer

KW - Tumor suppressor

KW - Tumor survival

UR - http://www.scopus.com/inward/record.url?scp=84901494319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901494319&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.04.016

DO - 10.1016/j.canlet.2014.04.016

M3 - Article

C2 - 24769074

AN - SCOPUS:84901494319

VL - 350

SP - 25

EP - 33

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1-2

ER -